Are there any biomarkers that might indicate who might be responders to atezolizumab/bevacizumab for HCC?

Not at this time. Some preliminary studies are being done as ad hoc at this point and was not pre specified before the IMbrave study launching

At this point nothing simple. There was some data presented at AACR 2020 from the single arm study but it looked at signatures. There were interesting findings but not ready for clinical practice